- Home
- VRNT vs PHVS Comparison
VRNT vs PHVS Comparison
Compare VRNT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- PHVS
- Stock Information
- Founded
- VRNT 1994
- PHVS 2015
- Country
- VRNT United States
- PHVS Switzerland
- Employees
- VRNT N/A
- PHVS N/A
- Industry
- VRNT EDP Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- PHVS Health Care
- Exchange
- VRNT Nasdaq
- PHVS Nasdaq
- Market Cap
- VRNT 1.1B
- PHVS 909.5M
- IPO Year
- VRNT N/A
- PHVS 2021
- Fundamental
- Price
- VRNT $17.22
- PHVS $16.49
- Analyst Decision
- VRNT Buy
- PHVS Strong Buy
- Analyst Count
- VRNT 6
- PHVS 5
- Target Price
- VRNT $30.33
- PHVS $39.20
- AVG Volume (30 Days)
- VRNT 622.2K
- PHVS 59.6K
- Earning Date
- VRNT 06-04-2025
- PHVS 05-13-2025
- Dividend Yield
- VRNT N/A
- PHVS N/A
- EPS Growth
- VRNT 273.67
- PHVS N/A
- EPS
- VRNT 1.04
- PHVS N/A
- Revenue
- VRNT $909,186,000.00
- PHVS N/A
- Revenue This Year
- VRNT $7.89
- PHVS N/A
- Revenue Next Year
- VRNT $5.20
- PHVS N/A
- P/E Ratio
- VRNT $16.56
- PHVS N/A
- Revenue Growth
- VRNT N/A
- PHVS N/A
- 52 Week Low
- VRNT $14.15
- PHVS $11.51
- 52 Week High
- VRNT $38.17
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- VRNT 45.84
- PHVS 51.83
- Support Level
- VRNT $16.35
- PHVS $15.46
- Resistance Level
- VRNT $17.90
- PHVS $16.99
- Average True Range (ATR)
- VRNT 0.51
- PHVS 1.04
- MACD
- VRNT -0.01
- PHVS -0.08
- Stochastic Oscillator
- VRNT 33.98
- PHVS 71.48
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.